ILP100-Topical
Wound healing (e.g., in SAVI patients)
Phase 2/3Active
Key Facts
About Ilya Pharma
Ilya Pharma is a clinical-stage biotech pioneering a novel therapeutic modality using engineered, non-colonizing lactic acid bacteria to produce therapeutic proteins locally at disease sites. Its lead asset, ILP100 (emilimogene sigulactibac), expresses CXCL12 and is in development for topical wound healing and oral treatment of colitis, with positive Phase 1/2 data. The platform aims to unlock a wide range of previously undruggable proteins with a favorable cost and safety profile, targeting significant unmet needs in wound care, gastrointestinal diseases, and rare genetic conditions.
View full company profile